Overview
Melinda Burgess practices in Brisbane, Australia. Ms. Burgess is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Leukemia.
Her clinical research consists of co-authoring 24 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles in the study of Chronic B-Cell Leukemia (CBCL).
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Chronic B-Cell Leukemia (CBCL)Ms. Burgess isAdvanced. Learn about Chronic B-Cell Leukemia (CBCL).
- Chronic Lymphocytic Leukemia (CLL)Ms. Burgess isAdvanced. Learn about Chronic Lymphocytic Leukemia (CLL).
- Small Lymphocytic Lymphoma (SLL)Ms. Burgess isAdvanced. Learn about Small Lymphocytic Lymphoma (SLL).
- Experienced
- B-Cell LymphomaMs. Burgess isExperienced. Learn about B-Cell Lymphoma.
- Diffuse Large B-Cell Lymphoma (DLBCL)Ms. Burgess isExperienced. Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
- Follicular LymphomaMs. Burgess isExperienced. Learn about Follicular Lymphoma.
- Hairy Cell Leukemia (HCL)Ms. Burgess isExperienced. Learn about Hairy Cell Leukemia (HCL).
- LeukemiaMs. Burgess isExperienced. Learn about Leukemia.
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)